Mobile Site ›

Chronic Lymphocytic Leukemia

New Approaches for a Common Disease

CLL and Minimal Residual Disease (MRD)

Slide 25

October 2008

Does immunohistochemistry (IHC) have a role in bone marrow specimens?
I would say that stains are often complementary to flow studies, but they are often hard to interpret in isolation away from flow studies. One also needs to be aware that T-cell nodules depleted of B-cells may be identified in patients who have been treated with Rituxan and clearly can be confused with CLL on a strict morphology basis.

What antibodies should be used for IHC?
There is no specific and easy answer. A variety of B-cell antibodies have been used, I would say that CD20 however has a minimal role because of the Rituxan effect; T-cell markers are also frequently done. However, CD5 may be hard to interpret in these cases.

Minimal Residual Disease (MRD)


Jump to section: